    6         ADVERSE REACTIONS  

  The following adverse reactions are discussed in greater detail in other sections of the labeling:

 *   Cardiac≠B-OSE_Labeled_AE   Toxicities≠I-OSE_Labeled_AE  [see   Warnings and Precautions  (    5.1    )]  
 *   Acute≠B-OSE_Labeled_AE   Renal≠I-OSE_Labeled_AE   Failure≠I-OSE_Labeled_AE   [see   Warnings and Precautions  (    5.2    )]  
 *   Tumor≠B-OSE_Labeled_AE   Lysis≠I-OSE_Labeled_AE   Syndrome≠I-OSE_Labeled_AE  [see   Warnings and Precautions  (    5.3    )]  
 *   Pulmonary≠B-OSE_Labeled_AE   Toxicity≠I-OSE_Labeled_AE  [see   Warnings and Precautions  (    5.4    )]  
 *   Pulmonary≠B-OSE_Labeled_AE   Hypertension≠I-OSE_Labeled_AE   [see   Warnings and Precautions  (    5.5    )]  
 *   Dyspnea≠B-OSE_Labeled_AE  [see   Warnings and Precautions  (    5.6    )]  
 *   Hypertension≠B-OSE_Labeled_AE  [see   Warnings and Precautions  (    5.7    )]  
 *   Venous≠B-OSE_Labeled_AE   Thrombosis≠I-OSE_Labeled_AE  [see   Warnings and Precautions  (    5.8    )]  
 *   Infusion≠B-OSE_Labeled_AE   Reactions≠I-OSE_Labeled_AE  [see   Warnings and Precautions  (    5.9    )]  
 *   Hemorrhage≠B-OSE_Labeled_AE  [see   Warnings and Precautions (    5.10    )]  
 *   Thrombocytopenia≠B-OSE_Labeled_AE  [see Warnings and Precautions  (    5.11    )]  
 *   Hepatic≠B-OSE_Labeled_AE   Toxicity≠I-OSE_Labeled_AE  and  Hepatic≠B-OSE_Labeled_AE   Failure≠I-OSE_Labeled_AE  [see   Warnings and Precautions  (    5.12    )]  
 *   Thrombotic≠B-OSE_Labeled_AE   Microangiopathy≠I-OSE_Labeled_AE   [see   Warnings and Precautions  (    5.13    )]  
 *   Posterior≠B-OSE_Labeled_AE   Reversible≠I-OSE_Labeled_AE   Encephalopathy≠I-OSE_Labeled_AE   Syndrome≠I-OSE_Labeled_AE  [see   Warnings and Precautions   (    5.14    )]  
 *  Increased  Fatal≠B-NonOSE_AE  and Serious Toxicities in Combintaion with Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Patients [see   Warnings and Precautions (    5.15    )]  
      EXCERPT:   The most common adverse reactions occurring in at least 20% of patients treated with Kyprolis in monotherapy trials:  anemia, fatigue, thrombocytopenia, nausea, pyrexia, dyspnea, diarrhea, headache, cough, edema peripheral. (  6  )
 

    

 The most common adverse reactions occurring in at least 20% of patients treated with Kyprolis in the combination therapy trials: anemia, neutropenia, diarrhea, dyspnea, fatigue, thrombocytopenia, pyrexia, insomnia, muscle spasm, cough, upper respiratory tract infection, hypokalemia. (  6  )

   To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  

 

  6.1       Clinical Trials Experience

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug, and may not reflect the rates observed in medical practice.

   Safety Experience with Kyprolis in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma  

 The safety of Kyprolis in combination with lenalidomide and dexamethasone (KRd) was evaluated in an open-label randomized study in patients with relapsed  multiple≠B-Not_AE_Candidate   myeloma≠I-Not_AE_Candidate . Details of the study treatment are described in Section 14.1.  The median number of cycles initiated was 22 cycles for the KRd arm and 14 cycles for the Rd arm.

  Deaths≠B-NonOSE_AE  due to adverse reactions within 30 days of the last dose of any therapy in the KRd arm occurred in 27/392 (7%) patients compared with 27/389 (7%) patients who  died≠B-NonOSE_AE  due to adverse events within 30 days of the last dose of any Rd therapy. The most common cause of  deaths≠B-NonOSE_AE  occurring in patients (%) in the two arms (KRd  versus  Rd) included  cardiac≠B-NonOSE_AE  10 (3%)  versus  7 (2%),  infection≠B-NonOSE_AE  9 (2%)  versu    s  10 (3%),  renal≠B-NonOSE_AE  0 (0%)  versus  1 (< 1%), and other adverse reactions 9 (2%)  versus  10 (3%). Serious adverse reactions were reported in 60% of the patients in the KRd arm and 54% of the patients in the Rd arm. The most common serious adverse reactions reported in the KRd arm as compared with the Rd arm were  pneumonia≠B-OSE_Labeled_AE  (14%  versus  11%),  respiratory≠B-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE  (4%  versus  1.5%),  pyrexia≠B-OSE_Labeled_AE  (4%  versus  2%), and  pulmonary≠B-OSE_Labeled_AE   embolism≠I-OSE_Labeled_AE  (3%  versus  2%). Discontinuation due to any adverse reaction occurred in 26% in the KRd arm  versus  25% in the Rd arm. Adverse reactions leading to discontinuation of Kyprolis occurred in 12% of patients and the most common reactions included  pneumonia≠B-OSE_Labeled_AE  (1%),  myocardial≠B-OSE_Labeled_AE   infarction≠I-OSE_Labeled_AE  (0.8%), and  upper≠B-OSE_Labeled_AE   respiratory≠I-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE  (0.8%).

   Common Adverse    Reactions    (    >=         10%)  

 The adverse reactions in the first 12 cycles of therapy that occurred at a rate of 10% or greater in the KRd arm are presented in Table 8.

 Table 8:  Most Common Adverse Reactions (>= 10% in the KRd Arm)  Occurring in Cycles 1-12  (20/27 mg/m2 Regimen In Combination with Lenalidomide and Dexamethasone) 
                    KRd Arm    (N         =         392)    n (%)      Rd Arm    (N         =         389)    n (%)     
               Adverse Reactions by Body System      Any Grade        >=         Grade         3      Any Grade        >=         Grade         3     
    Blood≠B-NonOSE_AE   and≠I-NonOSE_AE   Lymphatic≠I-NonOSE_AE   System≠I-NonOSE_AE   Disorders≠I-NonOSE_AE      
        Anemia≠B-OSE_Labeled_AE      138 (35)         53 (14)          127 (33)         47 (12)           
        Neutropenia≠B-OSE_Labeled_AE   124 (32)         104 (27)         115 (30)         89 (23)           
        Thrombocytopenia≠B-OSE_Labeled_AE   100 (26)         58 (15)          75 (19)          39 (10)           
    Gastrointestinal≠B-NonOSE_AE   Disorders≠I-NonOSE_AE      
        Diarrhea≠B-OSE_Labeled_AE    115 (29)         7 (2)            105 (27)         12 (3)            
        Constipation≠B-OSE_Labeled_AE   68 (17)          0                53 (14)          1 (0)             
        Nausea≠B-OSE_Labeled_AE      60 (15)          1 (0)            39 (10)          3 (1)             
    General≠B-NonOSE_AE   Disorders≠I-NonOSE_AE   and≠I-NonOSE_AE   Administration≠I-NonOSE_AE   Site≠I-NonOSE_AE   Conditions≠I-NonOSE_AE      
        Fatigue≠B-OSE_Labeled_AE     109 (28)         21 (5)           104 (27)         20 (5)            
        Pyrexia≠B-OSE_Labeled_AE     93 (24)          5 (1)            64 (17)          1 (0)             
        Edema≠B-OSE_Labeled_AE   peripheral≠I-OSE_Labeled_AE   63 (16)          2 (1)            57 (15)          2 (1)             
        Asthenia≠B-OSE_Labeled_AE    53 (14)          11 (3)           46 (12)          7 (2)             
    Infections≠B-NonOSE_AE   and≠I-NonOSE_AE   Infestations≠I-NonOSE_AE      
        Upper≠B-OSE_Labeled_AE   respiratory≠I-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE   85 (22)          7 (2)            52 (13)          3 (1)             
        Nasopharyngitis≠B-OSE_Labeled_AE   63 (16)          0                43 (11)          0                 
        Bronchitis≠B-OSE_Labeled_AE   54 (14)          5 (1)            39 (10)          2 (1)             
        Pneumonia≠B-OSE_Labeled_AE   a    54 (14)          35 (9)           43 (11)          27 (7)            
    Metabolism≠B-NonOSE_AE   and≠I-NonOSE_AE   Nutrition≠I-NonOSE_AE   Disorders≠I-NonOSE_AE      
        Hypokalemia≠B-OSE_Labeled_AE   78 (20)          22 (6)           35 (9)           12 (3)            
        Hypocalcemia≠B-OSE_Labeled_AE   55 (14)          10 (3)           39 (10)          5 (1)             
        Hyperglycemia≠B-OSE_Labeled_AE   43 (11)          18 (5)           33 (9)           15 (4)            
    Musculoskeletal≠B-NonOSE_AE   and≠I-NonOSE_AE   Connective≠I-NonOSE_AE   Tissue≠I-NonOSE_AE   Disorders≠I-NonOSE_AE      
        Muscle≠B-OSE_Labeled_AE   spasms≠I-OSE_Labeled_AE   88 (22)          3 (1)            73 (19)          3 (1)             
    Nervous≠B-NonOSE_AE   System≠I-NonOSE_AE   Disorders≠I-NonOSE_AE      
        Peripheral≠B-OSE_Labeled_AE   neuropathies≠I-OSE_Labeled_AE   b    43 (11)          7 (2)            37 (10)          4 (1)             
    Psychiatric≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                                                          
        Insomnia≠B-OSE_Labeled_AE    63 (16)          6 (2)            50 (13)          8 (2)             
    Respiratory≠B-NonOSE_AE  ,≠I-NonOSE_AE   Thoracic≠I-NonOSE_AE  ,≠I-NonOSE_AE   and≠I-NonOSE_AE   Mediastinal≠I-NonOSE_AE   Disorders≠I-NonOSE_AE      
        Cough≠B-OSE_Labeled_AE   c    91 (23)          2 (1)            52 (13)          0                 
        Dyspnea≠B-OSE_Labeled_AE   d    70 (18)          9 (2)            58 (15)          6 (2)             
    Skin≠B-NonOSE_AE   and≠I-NonOSE_AE   Subcutaneous≠I-NonOSE_AE   Tissue≠I-NonOSE_AE   Disorders≠I-NonOSE_AE      
        Rash≠B-OSE_Labeled_AE        45 (12)          5 (1)            53 (14)          5 (1)             
    Vascular≠B-NonOSE_AE   Disorders≠I-NonOSE_AE      
        Embolic≠B-OSE_Labeled_AE  and thrombotic  events≠I-OSE_Labeled_AE   venous≠I-OSE_Labeled_AE   e    49 (13)          16 (4)           22 (6)           9 (2)             
        Hypertension≠B-OSE_Labeled_AE   f    41 (11)          12 (3)           15 (4)           4 (1)             
 KRd = Kyprolis, lenalidomide, and dexamethasone; Rd = lenalidomide and dexamethasone  a    Pneumonia≠B-OSE_Labeled_AE  includes  pneumonia≠B-OSE_Labeled_AE  and  bronchopneumonia≠B-OSE_Labeled_AE .  b    Peripheral≠B-OSE_Labeled_AE   neuropathies≠I-OSE_Labeled_AE  includes  peripheral≠B-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE ,  peripheral≠B-OSE_Labeled_AE   sensory≠I-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE , and  peripheral≠B-OSE_Labeled_AE   motor≠I-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE .  c   Cough≠B-OSE_Labeled_AE  includes  cough≠B-OSE_Labeled_AE  and  productive≠B-OSE_Labeled_AE   cough≠I-OSE_Labeled_AE .  d    Dyspnea≠B-OSE_Labeled_AE  includes  dyspnea≠B-OSE_Labeled_AE  and  dyspnea≠B-OSE_Labeled_AE   exertional≠I-OSE_Labeled_AE .  e    Embolic≠B-OSE_Labeled_AE  and thrombotic      events≠I-OSE_Labeled_AE ,  venous≠I-OSE_Labeled_AE  include  deep≠B-OSE_Labeled_AE   vein≠I-OSE_Labeled_AE   thrombosis≠I-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   embolism≠I-OSE_Labeled_AE ,  thrombophlebitis≠B-OSE_Labeled_AE   superficial≠I-OSE_Labeled_AE ,  thrombophlebitis≠B-OSE_Labeled_AE ,  venous≠B-OSE_Labeled_AE   thrombosis≠I-OSE_Labeled_AE   limb≠I-OSE_Labeled_AE ,  post≠B-OSE_Labeled_AE   thrombotic≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE ,  venous≠B-OSE_Labeled_AE   thrombosis≠I-OSE_Labeled_AE .  f    Hypertension≠B-OSE_Labeled_AE  includes  hypertension≠B-OSE_Labeled_AE ,  hypertensive≠B-OSE_Labeled_AE   crisis≠I-OSE_Labeled_AE .   
           There were 274 (70%) patients in the KRd arm who received treatment beyond Cycle 12. There were no new clinically relevant adverse reactions that emerged in the later treatment cycles.
 

   Adverse Reactions Occurring at a Frequency of <         10%  

 *    Blood≠B-NonOSE_AE   and≠I-NonOSE_AE   lymphatic≠I-NonOSE_AE   system≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  febrile≠B-OSE_Labeled_AE   neutropenia≠I-OSE_Labeled_AE ,  lymphopenia≠B-OSE_Labeled_AE  
 *    Cardiac≠B-NonOSE_AE   disorders≠I-NonOSE_AE :    cardiac≠B-OSE_Labeled_AE   arrest≠I-OSE_Labeled_AE ,  cardiac≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  cardiac≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE   congestive≠I-OSE_Labeled_AE ,  myocardial≠B-OSE_Labeled_AE   infarction≠I-OSE_Labeled_AE ,  myocardial≠B-OSE_Labeled_AE   ischemia≠I-OSE_Labeled_AE ,  pericardial≠B-OSE_Labeled_AE   effusion≠I-OSE_Labeled_AE  
 *    Eye≠B-NonOSE_AE   disorders≠I-NonOSE_AE :  cataract≠B-OSE_Labeled_AE ,  vision≠B-OSE_Labeled_AE   blurred≠I-OSE_Labeled_AE  
 *    Gastrointestinal≠B-NonOSE_AE   disorders≠I-NonOSE_AE :  abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE   upper≠I-OSE_Labeled_AE ,  dyspepsia≠B-OSE_Labeled_AE ,  gastrointestinal≠B-OSE_Labeled_AE   hemorrhage≠I-OSE_Labeled_AE ,  toothache≠B-OSE_Labeled_AE  
 *    General≠B-NonOSE_AE   disorders≠I-NonOSE_AE   and≠I-NonOSE_AE   administration≠I-NonOSE_AE   site≠I-NonOSE_AE   conditions≠I-NonOSE_AE :  chills≠B-OSE_Labeled_AE ,  infusion≠B-OSE_Labeled_AE   site≠I-OSE_Labeled_AE   reaction≠I-OSE_Labeled_AE ,  multi≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  organ≠I-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  pain≠B-OSE_Labeled_AE  
 *    Infections≠B-NonOSE_AE   and≠I-NonOSE_AE   infestations≠I-NonOSE_AE :  influenza≠B-OSE_Labeled_AE ,  lung≠B-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE ,  rhinitis≠B-OSE_Labeled_AE ,  sepsis≠B-OSE_Labeled_AE ,  urinary≠B-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE ,  viral≠B-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE  
 *    Metabolism≠B-NonOSE_AE   and≠I-NonOSE_AE   nutrition≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  dehydration≠B-OSE_Labeled_AE ,  hyperkalemia≠B-OSE_Labeled_AE ,  hyperuricemia≠B-OSE_Labeled_AE ,  hypoalbuminemia≠B-OSE_Labeled_AE ,  hyponatremia≠B-OSE_Labeled_AE ,  tumor≠B-OSE_Labeled_AE   lysis≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE  
 *    Musculoskeletal≠B-NonOSE_AE   and≠I-NonOSE_AE   connective≠I-NonOSE_AE   tissue≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  muscular≠B-OSE_Labeled_AE   weakness≠I-OSE_Labeled_AE ,  myalgia≠B-OSE_Labeled_AE  
 *    Nervous≠B-NonOSE_AE   system≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  hypoesthesia≠B-OSE_Labeled_AE ,  intracranial≠B-OSE_Labeled_AE   hemorrhage≠I-OSE_Labeled_AE ,  paresthesia≠B-OSE_Labeled_AE ,  deafness≠B-OSE_Labeled_AE  
 *    Psychiatric≠B-NonOSE_AE   disorders≠I-NonOSE_AE :  anxiety≠B-OSE_Labeled_AE ,  delirium≠B-OSE_Labeled_AE  
 *    Renal≠B-NonOSE_AE   and≠I-NonOSE_AE   urinary≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  renal≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  renal≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE   acute≠I-OSE_Labeled_AE ,  renal≠B-OSE_Labeled_AE   impairment≠I-OSE_Labeled_AE  
 *    Respiratory≠B-NonOSE_AE  ,≠I-NonOSE_AE   thoracic≠I-NonOSE_AE   and≠I-NonOSE_AE   mediastinal≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  dysphonia≠B-OSE_Labeled_AE ,  epistaxis≠B-OSE_Labeled_AE ,  oropharyngeal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   embolism≠I-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   edema≠I-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   hemorrhage≠I-OSE_Labeled_AE   
 *    Skin≠B-NonOSE_AE   and≠I-NonOSE_AE   subcutaneous≠I-NonOSE_AE   tissue≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  erythema≠B-OSE_Labeled_AE ,  hyperhidrosis≠B-OSE_Labeled_AE ,  pruritus≠B-OSE_Labeled_AE  
 *    Vascular≠B-NonOSE_AE   disorders≠I-NonOSE_AE :  deep≠B-OSE_Labeled_AE   vein≠I-OSE_Labeled_AE   thrombosis≠I-OSE_Labeled_AE ,  hemorrhage≠B-OSE_Labeled_AE ,  hypotension≠B-OSE_Labeled_AE  
    Grade 3 and higher adverse reactions that occurred during Cycles 1-12 with a substantial difference (>= 2%) between the two arms were  neutropenia≠B-OSE_Labeled_AE ,  thrombocytopenia≠B-OSE_Labeled_AE ,  hypokalemia≠B-OSE_Labeled_AE , and  hypophosphatemia≠B-OSE_Labeled_AE .
 

   Laboratory Abnormalities  

 Table 9 describes Grade 3-4  laboratory≠B-NonOSE_AE   abnormalities≠I-NonOSE_AE  reported at a rate of >= 10% in the KRd arm for patients who received combination therapy.

 Table 9: Grade 3-4 Laboratory Abnormalities (>= 10% in the KRd Arm) in Cycles 1-12 (20/27 mg/m2 Regimen In Combination with Lenalidomide and Dexamethasone) 
    Laboratory≠B-NonOSE_AE   Abnormality≠I-NonOSE_AE       KRd    (N         =         392)    n (%)      Rd    (N         =         389)    n (%)     
  Decreased≠B-OSE_Labeled_AE   lymphocytes≠I-OSE_Labeled_AE   182 (46)         119 (31)          
  Decreased≠B-OSE_Labeled_AE   absolute≠I-OSE_Labeled_AE   neutrophil≠I-OSE_Labeled_AE   count≠I-OSE_Labeled_AE   152 (39)         140 (36)          
  Decreased≠B-OSE_Labeled_AE   phosphorus≠I-OSE_Labeled_AE   122 (31)         106 (27)          
  Decreased≠B-OSE_Labeled_AE   platelets≠I-OSE_Labeled_AE   101 (26)         59 (15)           
  Decreased≠B-OSE_Labeled_AE   total≠I-OSE_Labeled_AE   white≠I-OSE_Labeled_AE   blood≠I-OSE_Labeled_AE   cell≠I-OSE_Labeled_AE   count≠I-OSE_Labeled_AE   97 (25)          71 (18)           
  Decreased≠B-OSE_Labeled_AE   hemoglobin≠I-OSE_Labeled_AE   58 (15)          68 (18)           
  Decreased≠B-OSE_Labeled_AE   potassium≠I-OSE_Labeled_AE   41 (11)          23 (6)            
 KRd = Kyprolis, lenalidomide, and dexamethasone; Rd = lenalidomide and dexamethasone   
           Safety Experience with Kyprolis    in Combination with Dexamethasone    in Patients with Multiple Myeloma  
 

 The safety of Kyprolis in combination with dexamethasone was evaluated in an open-label, randomized trial of patients with relapsed  multiple≠B-Not_AE_Candidate   myeloma≠I-Not_AE_Candidate . The study treatment is described in Section 14.2.  Patients received treatment for a median duration of 40 weeks in the Kyprolis/dexamethasone (Kd) arm and 27 weeks in the bortezomib/dexamethasone (Vd) arm.

  Deaths≠B-NonOSE_AE  due to adverse reactions within 30 days of last study treatment occurred in 22/463 (5%) patients in the Kd arm and 21/456 (5%) patients in the Vd arm. The causes of  death≠B-NonOSE_AE  occurring in patients (%) in the two arms (Kd  versus  Vd) included  cardiac≠B-NonOSE_AE  7 (2%)  versus  5 (1%),  infections≠B-NonOSE_AE  5 (1%)  versus  8 (2%), disease progression 6 (1%)  versus  4 (1%),  pulmonary≠B-NonOSE_AE  3 (1%)  versus  2 (< 1%),  renal≠B-NonOSE_AE  1 (< 1%)  versus  0 (0%), and other adverse events 2 (< 1%)  versus  2 (< 1%). Serious adverse reactions were reported in 48% of the patients in the Kd arm and 36% of the patients in the Vd arm. In both treatment arms,  pneumonia≠B-OSE_Labeled_AE  was the most commonly reported serious adverse reaction (6%  versus  9%). Discontinuation due to any adverse reaction occurred in 20% in the Kd arm  versus  21% in the Vd arm. The most common reaction leading to discontinuation was  cardiac≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE  in the Kd arm (n = 6, 1.3%) and  peripheral≠B-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE  in the Vd arm (n = 19, 4.2%).

   Common Adverse    Reactions         (    >=         10%)  

 Adverse reactions in the first 6 months of therapy that occurred at a rate of 10% or greater in the Kd arm are presented in Table 10.

 Table 10: Most Common Adverse Reactions (>= 10% in the Kd Arm) Occurring in Months 1-6 (20/56 mg/m2 Regimen In Combination with Dexamethasone) 
                    Kd    (N         =         463)    n (%)      Vd    (N         =         456)    n (%)     
   Adverse Reaction by Body System      Any Grade        >=         Grade         3      Any Grade        >=         Grade         3     
    Blood≠B-NonOSE_AE   and≠I-NonOSE_AE      L≠I-NonOSE_AE      ymphatic≠I-NonOSE_AE      S≠I-NonOSE_AE      ystem≠I-NonOSE_AE      D≠I-NonOSE_AE      isorders≠I-NonOSE_AE      
       Anemia≠B-OSE_Labeled_AE       160 (35)         57 (12)          112 (25)         43 (9)            
       Thrombocytopenia≠B-OSE_Labeled_AE   a    127 (27)         46 (10)          112 (25)         65 (14)           
    Gastrointestinal≠B-NonOSE_AE      D≠I-NonOSE_AE      isorders≠I-NonOSE_AE      
       Diarrhea≠B-OSE_Labeled_AE     111 (24)         14 (3)           150 (33)         26 (6)            
       Nausea≠B-OSE_Labeled_AE       69 (15)          4 (1)            66 (15)          3 (1)             
       Constipation≠B-OSE_Labeled_AE   58 (13)          1 (0)            109 (24)         6 (1)             
       Vomiting≠B-OSE_Labeled_AE     45 (10)          5 (1)            32 (7)           3 (1)             
    General≠B-NonOSE_AE      D≠I-NonOSE_AE      isorders≠I-NonOSE_AE   and≠I-NonOSE_AE      A≠I-NonOSE_AE      dministration≠I-NonOSE_AE      S≠I-NonOSE_AE      ite≠I-NonOSE_AE      C≠I-NonOSE_AE      onditions≠I-NonOSE_AE      
       Fatigue≠B-OSE_Labeled_AE      112 (24)         13 (3)           124 (27)         25 (6)            
       Pyrexia≠B-OSE_Labeled_AE      102 (22)         9 (2)            52 (11)          3 (1)             
       Peripheral≠B-OSE_Labeled_AE   edema≠I-OSE_Labeled_AE   75 (16)          3 (1)            73 (16)          3 (1)             
       Asthenia≠B-OSE_Labeled_AE     71 (15)          9 (2)            66 (14)          13 (3)            
    Infections≠B-NonOSE_AE   and≠I-NonOSE_AE      I≠I-NonOSE_AE      nfestations≠I-NonOSE_AE      
       Upper≠B-OSE_Labeled_AE   respiratory≠I-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE   66 (14)          4 (1)            54 (12)          3 (1)             
       Bronchitis≠B-OSE_Labeled_AE   54 (12)          5 (1)            26 (6)           2 (0)             
       Nasopharyngitis≠B-OSE_Labeled_AE   45 (10)          0 (0)            42 (9)           1 (0)             
    Musculoskeletal≠B-NonOSE_AE   and≠I-NonOSE_AE      C≠I-NonOSE_AE      onnective≠I-NonOSE_AE      T≠I-NonOSE_AE      issue≠I-NonOSE_AE      D≠I-NonOSE_AE      isorders≠I-NonOSE_AE      
       Muscle≠B-OSE_Labeled_AE   spasms≠I-OSE_Labeled_AE   66 (14)          1 (0)            22 (5)           3 (1)             
       Back≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE    58 (13)          7 (2)            60 (13)          8 (2)             
    Nervous≠B-NonOSE_AE      S≠I-NonOSE_AE      ystem≠I-NonOSE_AE      D≠I-NonOSE_AE      isorders≠I-NonOSE_AE      
       Headache≠B-OSE_Labeled_AE     68 (15)          4 (1)            38 (8)           2 (0)             
       Peripheral≠B-OSE_Labeled_AE   neuropathies≠I-OSE_Labeled_AE   b    ,c    54 (12)          7 (2)            167 (37)         23 (5)            
    Psychiatric≠B-NonOSE_AE      D≠I-NonOSE_AE      isorders≠I-NonOSE_AE      
       Insomnia≠B-OSE_Labeled_AE     103 (22)         5 (1)            113 (25)         10 (2)            
    Respiratory≠B-NonOSE_AE  ,≠I-NonOSE_AE      T≠I-NonOSE_AE      horacic≠I-NonOSE_AE   and≠I-NonOSE_AE      M≠I-NonOSE_AE      ediastinal≠I-NonOSE_AE      D≠I-NonOSE_AE      isorders≠I-NonOSE_AE      
       Dyspnea≠B-OSE_Labeled_AE   d    123 (27)         23 (5)           66 (15)          8 (2)             
       Cough≠B-OSE_Labeled_AE   e    91 (20)          0 (0)            61 (13)          2 (0)             
    Vascular≠B-NonOSE_AE   Disorders≠I-NonOSE_AE      
       Hypertension≠B-OSE_Labeled_AE   f    80 (17)          29 (6)           33 (7)           12 (3)            
 Kd = Kyprolis and dexamethasone; Vd = bortezomib and dexamethasone  a    Thrombocytopenia≠B-OSE_Labeled_AE  includes  platelet≠B-OSE_Labeled_AE   count≠I-OSE_Labeled_AE   decreased≠I-OSE_Labeled_AE  and  thrombocytopenia≠B-OSE_Labeled_AE .  b    Peripheral≠B-OSE_Labeled_AE   neuropathies≠I-OSE_Labeled_AE  include  peripheral≠B-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE ,  peripheral≠B-OSE_Labeled_AE   sensory≠I-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE , and  peripheral≠B-OSE_Labeled_AE   motor≠I-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE .  c  See Clinical Studies (14.2).  d    Dyspnea≠B-OSE_Labeled_AE  includes  dyspnea≠B-OSE_Labeled_AE  and  dyspnea≠B-OSE_Labeled_AE   exertional≠I-OSE_Labeled_AE .  e   Cough≠B-OSE_Labeled_AE  includes  cough≠B-OSE_Labeled_AE  and  productive≠B-OSE_Labeled_AE   cough≠I-OSE_Labeled_AE .  f    Hypertension≠B-OSE_Labeled_AE  includes  hypertension≠B-OSE_Labeled_AE ,  hypertensive≠B-OSE_Labeled_AE   crisis≠I-OSE_Labeled_AE , and  hypertensive≠B-OSE_Labeled_AE   emergency≠I-OSE_Labeled_AE .   
            The event rate of >= Grade 2  peripheral≠B-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE  in the Kd arm was 6% (95% CI:  4, 8)  versus  32% (95% CI:  28, 36) in the Vd arm.
 

   Adverse Reactions Occurring at a Frequency of <         10%  

 *    Blood≠B-NonOSE_AE   and≠I-NonOSE_AE   lymphatic≠I-NonOSE_AE   system≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  febrile≠B-OSE_Labeled_AE   neutropenia≠I-OSE_Labeled_AE ,  leukopenia≠B-OSE_Labeled_AE ,  lymphopenia≠B-OSE_Labeled_AE ,  neutropenia≠B-OSE_Labeled_AE ,  thrombotic≠B-OSE_Labeled_AE   microangiopathy≠I-OSE_Labeled_AE ,  thrombotic≠B-OSE_Labeled_AE   thrombocytopenic≠I-OSE_Labeled_AE   purpura≠I-OSE_Labeled_AE  
 *    Cardiac≠B-NonOSE_AE   disorders≠I-NonOSE_AE :    atrial≠B-OSE_Labeled_AE   fibrillation≠I-OSE_Labeled_AE ,  cardiac≠B-OSE_Labeled_AE   arrest≠I-OSE_Labeled_AE ,  cardiac≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  cardiac≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE   congestive≠I-OSE_Labeled_AE ,  myocardial≠B-OSE_Labeled_AE   infarction≠I-OSE_Labeled_AE ,  myocardial≠B-OSE_Labeled_AE   ischemia≠I-OSE_Labeled_AE ,  palpitations≠B-OSE_Labeled_AE ,  tachycardia≠B-OSE_Labeled_AE  
 *    Eye≠B-NonOSE_AE   disorders≠I-NonOSE_AE :  cataract≠B-OSE_Labeled_AE ,  vision≠B-OSE_Labeled_AE   blurred≠I-OSE_Labeled_AE  
 *    Gastrointestinal≠B-NonOSE_AE   disorders≠I-NonOSE_AE :  abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE   upper≠I-OSE_Labeled_AE ,  dyspepsia≠B-OSE_Labeled_AE ,  gastrointestinal≠B-OSE_Labeled_AE   hemorrhage≠I-OSE_Labeled_AE ,  toothache≠B-OSE_Labeled_AE  
 *    General≠B-NonOSE_AE   disorders≠I-NonOSE_AE   and≠I-NonOSE_AE   administration≠I-NonOSE_AE   site≠I-NonOSE_AE   conditions≠I-NonOSE_AE :  chest≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  chills≠B-OSE_Labeled_AE ,  infusion≠B-OSE_Labeled_AE   site≠I-OSE_Labeled_AE   reactions≠I-OSE_Labeled_AE  (including  inflammation≠B-OSE_Labeled_AE ,  pain≠B-OSE_Labeled_AE , and  erythema≠B-OSE_Labeled_AE ),  pain≠B-OSE_Labeled_AE  
 *    Hepatobiliary≠B-NonOSE_AE   disorders≠I-NonOSE_AE :  cholestasis≠B-OSE_Labeled_AE ,  hepatic≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  hyperbilirubinemia≠B-OSE_Labeled_AE  
 *    Immune≠B-NonOSE_AE   system≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  drug≠B-OSE_Labeled_AE   hypersensitivity≠I-OSE_Labeled_AE  
 *    Infections≠B-NonOSE_AE   and≠I-NonOSE_AE   infestations≠I-NonOSE_AE :  bronchopneumonia≠B-OSE_Labeled_AE ,  influenza≠B-OSE_Labeled_AE ,  lung≠B-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE ,  pneumonia≠B-OSE_Labeled_AE ,  rhinitis≠B-OSE_Labeled_AE ,  sepsis≠B-OSE_Labeled_AE ,  urinary≠B-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE ,  viral≠B-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE  
 *    Metabolism≠B-NonOSE_AE   and≠I-NonOSE_AE   nutrition≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  decreased≠B-OSE_Labeled_AE   appetite≠I-OSE_Labeled_AE ,  dehydration≠B-OSE_Labeled_AE ,  hypercalcemia≠B-OSE_Labeled_AE ,  hyperkalemia≠B-OSE_Labeled_AE ,  hyperuricemia≠B-OSE_Labeled_AE ,  hypoalbuminemia≠B-OSE_Labeled_AE ,  hypocalcemia≠B-OSE_Labeled_AE ,  hypomagnesemia≠B-OSE_Labeled_AE ,  hyponatremia≠B-OSE_Labeled_AE ,  hypophosphatemia≠B-OSE_Labeled_AE ,  tumor≠B-OSE_Labeled_AE   lysis≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE  
 *    Musculoskeletal≠B-NonOSE_AE   and≠I-NonOSE_AE   connective≠I-NonOSE_AE   tissue≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  muscular≠B-OSE_Labeled_AE   weakness≠I-OSE_Labeled_AE ,  musculoskeletal≠B-OSE_Labeled_AE   chest≠I-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  musculoskeletal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  myalgia≠B-OSE_Labeled_AE  
 *    Nervous≠B-NonOSE_AE   system≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  cerebrovascular≠B-OSE_Labeled_AE   accident≠I-OSE_Labeled_AE ,  dizziness≠B-OSE_Labeled_AE ,  hypoesthesia≠B-OSE_Labeled_AE ,  paresthesia≠B-OSE_Labeled_AE ,  posterior≠B-OSE_Labeled_AE   reversible≠I-OSE_Labeled_AE   encephalopathy≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE  
 *    Psychiatric≠B-NonOSE_AE   disorders≠I-NonOSE_AE :  anxiety≠B-OSE_Labeled_AE  
 *    Renal≠B-NonOSE_AE   and≠I-NonOSE_AE   urinary≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  renal≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  renal≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE   acute≠I-OSE_Labeled_AE ,  renal≠B-OSE_Labeled_AE   impairment≠I-OSE_Labeled_AE  
 *    Respiratory≠B-NonOSE_AE  ,≠I-NonOSE_AE   thoracic≠I-NonOSE_AE   and≠I-NonOSE_AE   mediastinal≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  acute≠B-OSE_Labeled_AE   respiratory≠I-OSE_Labeled_AE   distress≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE ,  dysphonia≠B-OSE_Labeled_AE ,  epistaxis≠B-OSE_Labeled_AE ,  interstitial≠B-OSE_Labeled_AE   lung≠I-OSE_Labeled_AE   disease≠I-OSE_Labeled_AE ,  oropharyngeal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  pneumonitis≠B-OSE_Labeled_AE   pulmonary≠B-OSE_Labeled_AE   embolism≠I-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   edema≠I-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   hypertension≠I-OSE_Labeled_AE ,  wheezing≠B-OSE_Labeled_AE  
 *    Skin≠B-NonOSE_AE   and≠I-NonOSE_AE   subcutaneous≠I-NonOSE_AE   tissue≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  erythema≠B-OSE_Labeled_AE ,  hyperhidrosis≠B-OSE_Labeled_AE ,  pruritus≠B-OSE_Labeled_AE ,  rash≠B-OSE_Labeled_AE  
 *    Vascular≠B-NonOSE_AE   disorders≠I-NonOSE_AE :  deep≠B-OSE_Labeled_AE   vein≠I-OSE_Labeled_AE   thrombosis≠I-OSE_Labeled_AE ,  flushing≠B-OSE_Labeled_AE ,  hypotension≠B-OSE_Labeled_AE  
      Laboratory Abnormalities  
 

 Table 11 describes Grades 3-4  laboratory≠B-NonOSE_AE   abnormalities≠I-NonOSE_AE  reported at a rate of >= 10% in the Kd arm.

 Table 11: Grades 3-4 Laboratory Abnormalities (>= 10%) in Months 1-6 (20/56 mg/m2 Regimen In Combination with Dexamethasone) 
    Laboratory≠B-NonOSE_AE   Abnormality≠I-NonOSE_AE       Kd    (N         =         463)    n (%)      Vd    (N         =         456)    n (%)     
  Decreased≠B-OSE_Labeled_AE   lymphocytes≠I-OSE_Labeled_AE   248 (54)         180 (40)          
  Increase≠B-OSE_Labeled_AE   uric≠I-OSE_Labeled_AE   acid≠I-OSE_Labeled_AE   243 (53)         198 (43)          
  Decreased≠B-OSE_Labeled_AE   hemoglobin≠I-OSE_Labeled_AE   79 (17)          68 (15)           
  Decreased≠B-OSE_Labeled_AE   platelets≠I-OSE_Labeled_AE   85 (18)          77 (17)           
  Decreased≠B-OSE_Labeled_AE   phosphorus≠I-OSE_Labeled_AE   73 (16)          61 (13)           
  Decreased≠B-OSE_Labeled_AE   creatinine≠I-OSE_Labeled_AE   clearance≠I-OSE_Labeled_AE   a    65 (14)          49 (11)           
  Increased≠B-OSE_Labeled_AE   potassium≠I-OSE_Labeled_AE   55 (12)          21 (5)            
 Kd = Kyprolis and dexamethasone; Vd = bortezomib and dexamethasone  a  Calculated using the Cockcroft-Gault formula.   
           Safety Experience with Kyprolis in Patients with Multiple Myeloma who Received Monotherapy  
 

 The safety of Kyprolis, dosed at 20/27 mg/m  2  by up to 10-minute infusion, was evaluated in clinical trials in which 598 patients with relapsed and/or refractory  myeloma≠B-Not_AE_Candidate  received Kyprolis monotherapy starting with the 20 mg/m  2  dose in Cycle 1, Day 1 and escalating to 27 mg/m  2  on Cycle 1, Day 8 or Cycle 2, Day 1. Premedication with dexamethasone 4 mg was required before each dose in Cycle 1 and was optional for subsequent cycles. The median age was 64 years (range 32-87), and approximately 57% were male. The patients received a median of 5 (range 1-20) prior regimens. The median number of cycles initiated was 4 (range 1-35).

 Serious adverse reactions, regardless of causality, were reported in 50% of patients in the pooled Kyprolis monotherapy studies (N = 598).  The most common serious adverse reactions were:  pneumonia≠B-OSE_Labeled_AE  (8%),  acute≠B-OSE_Labeled_AE   renal≠I-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE  (5%),  disease≠B-OSE_Labeled_AE   progression≠I-OSE_Labeled_AE  (4%),  pyrexia≠B-OSE_Labeled_AE  (3%),  hypercalcemia≠B-OSE_Labeled_AE  (3%),  congestive≠B-OSE_Labeled_AE   heart≠I-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE  (3%),  multiple≠B-OSE_Labeled_AE   myeloma≠I-OSE_Labeled_AE  (3%),  anemia≠B-OSE_Labeled_AE  (2%), and  dyspnea≠B-OSE_Labeled_AE  (2%). In patients treated with Kyprolis, the incidence of serious adverse reactions was higher in those >= 65 years old and those >= 75 years old  [see Geriatric Use         (      8.5      )]  .

  Deaths≠B-NonOSE_AE  due to adverse reactions within 30 days of the last dose of Kyprolis occurred in 30/598 (5%) patients receiving Kyprolis monotherapy. These adverse reactions were related to  cardiac≠B-OSE_Labeled_AE   disorders≠I-OSE_Labeled_AE  in 10 (2%) patients,  infections≠B-OSE_Labeled_AE  in 8 (1%) patients,  renal≠B-OSE_Labeled_AE   disorders≠I-OSE_Labeled_AE  in 4 (< 1%) patients, and other adverse reactions in 8 (1%) patients.  In a randomized trial comparing Kyprolis as a single agent  versus  corticosteroids with optional oral cyclophosphamide for patients with relapsed and refractory  multiple≠B-Not_AE_Candidate   myeloma≠I-Not_AE_Candidate ,  mortality≠B-NonOSE_AE  was higher in the patients treated with Kyprolis in comparison to the control arm in the subgroup of 48 patients >= 75 years of age. The most common cause of discontinuation due to an adverse reaction was  acute≠B-OSE_Labeled_AE   renal≠I-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE  (2%).

 Safety of Kyprolis monotherapy dosed at 20/56 mg/m  2  by 30-minute infusion was evaluated in a multicenter, open-label study in patients with relapsed and/or refractory  multiple≠B-Not_AE_Candidate   myeloma≠I-Not_AE_Candidate .  The study treatment is described in Section 14.3. The patients received a median of 4 (range 1-10) prior regimens.

 The common adverse reactions occurring at a rate of 20% or greater with Kyprolis monotherapy are presented in Table 12.

 Table 12: Most Common Adverse Reactions (>= 20%) with Kyprolis Monotherapy  
                    20/56         mg/m      2      by 30  -  minute infusion    (N         =         24)      20/27         mg/m      2      by    2  -  to 10  -  minute infusion    (N         =         598)     
   Adverse Reaction      Any Grade    n (%)      Grades         3         -         5    n (%)      Any Grade    n (%)      Grades         3         -         5    n (%)     
  Fatigue≠B-OSE_Labeled_AE           14 (58)          2 (8)            238 (40)         25 (4)            
  Dyspnea≠B-OSE_Labeled_AE   a       14 (58)          2 (8)            202 (34)         21 (4)            
  Pyrexia≠B-OSE_Labeled_AE           14 (58)          0                177 (30)         11 (2)            
  Thrombocytopenia≠B-OSE_Labeled_AE   13 (54)          13 (54)          220 (37)         152 (25)          
  Nausea≠B-OSE_Labeled_AE            13 (54)          0                211 (35)         7 (1)             
  Anemia≠B-OSE_Labeled_AE            10 (42)          7 (29)           291 (49)         141 (24)          
  Hypertension≠B-OSE_Labeled_AE   b    10 (42)          3 (13)           90 (15)          22 (4)            
  Chills≠B-OSE_Labeled_AE            9 (38)           0                73 (12)          1 (< 1)           
  Headache≠B-OSE_Labeled_AE          8 (33)           0                141 (24)         7 (1)             
  Cough≠B-OSE_Labeled_AE   c         8 (33)           0                134 (22)         2 (< 1)           
  Vomiting≠B-OSE_Labeled_AE          8 (33)           0                104 (17)         4 (1)             
  Lymphopenia≠B-OSE_Labeled_AE       8 (33)           8 (33)           85 (14)          73 (12)           
  Insomnia≠B-OSE_Labeled_AE          7 (29)           0                75 (13)          0                 
  Dizziness≠B-OSE_Labeled_AE         7 (29)           0                64 (11)          5 (1)             
  Diarrhea≠B-OSE_Labeled_AE          6 (25)           1 (4)            160 (27)         8 (1)             
  Blood≠B-OSE_Labeled_AE   creatinine≠I-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE   6 (25)           1 (4)            103 (17)         15 (3)            
  Peripheral≠B-OSE_Labeled_AE   edema≠I-OSE_Labeled_AE   5 (21)           0                118 (20)         1 (< 1)           
  Back≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE         5 (21)           1 (4)            115 (19)         19 (3)            
  Upper≠B-OSE_Labeled_AE   respiratory≠I-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE   5 (21)           1 (4)            112 (19)         15 (3)            
  Decreased≠B-OSE_Labeled_AE   appetite≠I-OSE_Labeled_AE   5 (21)           0                89 (15)          2 (< 1)           
  Muscle≠B-OSE_Labeled_AE   spasms≠I-OSE_Labeled_AE     5 (21)           0                62 (10)          2 (< 1)           
  Chest≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE        5 (21)           0                20 (3)           1 (< 1)           
   a   Dyspnea≠B-OSE_Labeled_AE  includes preferred terms of  dyspnea≠B-OSE_Labeled_AE  and  dyspnea≠B-OSE_Labeled_AE   exertional≠I-OSE_Labeled_AE .  b   Hypertension≠B-OSE_Labeled_AE  includes  hypertension≠B-OSE_Labeled_AE ,  hypertensive≠B-OSE_Labeled_AE   crisis≠I-OSE_Labeled_AE , and  hypertensive≠B-OSE_Labeled_AE   emergency≠I-OSE_Labeled_AE .  c   Cough≠B-OSE_Labeled_AE  includes  cough≠B-OSE_Labeled_AE  and  productive≠B-OSE_Labeled_AE   cough≠I-OSE_Labeled_AE .   
             Adverse Reactions Occurring at a Frequency of <     20    %  
 

 *    Blood≠B-NonOSE_AE   and≠I-NonOSE_AE   lymphatic≠I-NonOSE_AE   system≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  febrile≠B-OSE_Labeled_AE   neutropenia≠I-OSE_Labeled_AE ,  leukopenia≠B-OSE_Labeled_AE ,  neutropenia≠B-OSE_Labeled_AE  
 *    Cardiac≠B-NonOSE_AE   disorders≠I-NonOSE_AE :    cardiac≠B-OSE_Labeled_AE   arrest≠I-OSE_Labeled_AE ,  cardiac≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  cardiac≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE   congestive≠I-OSE_Labeled_AE ,  myocardial≠B-OSE_Labeled_AE   infarction≠I-OSE_Labeled_AE ,  myocardial≠B-OSE_Labeled_AE   ischemia≠I-OSE_Labeled_AE  
 *    Eye≠B-NonOSE_AE   disorders≠I-NonOSE_AE :  cataract≠B-OSE_Labeled_AE ,  blurred≠B-OSE_Labeled_AE   vision≠I-OSE_Labeled_AE  
 *    Gastrointestinal≠B-NonOSE_AE   disorders≠I-NonOSE_AE :  abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE   upper≠I-OSE_Labeled_AE ,  constipation≠B-OSE_Labeled_AE ,  dyspepsia≠B-OSE_Labeled_AE ,  gastrointestinal≠B-OSE_Labeled_AE   hemorrhage≠I-OSE_Labeled_AE ,  toothache≠B-OSE_Labeled_AE  
 *    General≠B-NonOSE_AE   disorders≠I-NonOSE_AE   and≠I-NonOSE_AE   administration≠I-NonOSE_AE   site≠I-NonOSE_AE   conditions≠I-NonOSE_AE :    asthenia≠B-OSE_Labeled_AE ,  infusion≠B-OSE_Labeled_AE   site≠I-OSE_Labeled_AE   reaction≠I-OSE_Labeled_AE ,  multi≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  organ≠I-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  pain≠B-OSE_Labeled_AE  
 *    Hepatobiliary≠B-NonOSE_AE   disorders≠I-NonOSE_AE :  hepatic≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE  
 *    Infections≠B-NonOSE_AE   and≠I-NonOSE_AE   infestations≠I-NonOSE_AE :  bronchitis≠B-OSE_Labeled_AE ,  bronchopneumonia≠B-OSE_Labeled_AE ,  influenza≠B-OSE_Labeled_AE ,  lung≠B-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE ,  pneumonia≠B-OSE_Labeled_AE ,  nasopharyngitis≠B-OSE_Labeled_AE ,  respiratory≠B-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE ,  rhinitis≠B-OSE_Labeled_AE ,  sepsis≠B-OSE_Labeled_AE ,  urinary≠B-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE  
 *    Metabolism≠B-NonOSE_AE   and≠I-NonOSE_AE   nutrition≠I-NonOSE_AE   disorders≠I-NonOSE_AE :    hypercalcemia≠B-OSE_Labeled_AE ,  hyperglycemia≠B-OSE_Labeled_AE ,  hyperkalemia≠B-OSE_Labeled_AE ,  hyperuricemia≠B-OSE_Labeled_AE ,  hypoalbuminemia≠B-OSE_Labeled_AE ,  hypocalcemia≠B-OSE_Labeled_AE ,  hypokalemia≠B-OSE_Labeled_AE ,  hypomagnesemia≠B-OSE_Labeled_AE ,  hyponatremia≠B-OSE_Labeled_AE ,  hypophosphatemia≠B-OSE_Labeled_AE ,  tumor≠B-OSE_Labeled_AE   lysis≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE  
 *    Musculoskeletal≠B-NonOSE_AE   and≠I-NonOSE_AE   connective≠I-NonOSE_AE   tissue≠I-NonOSE_AE   disorders≠I-NonOSE_AE :    arthralgia≠B-OSE_Labeled_AE ,  musculoskeletal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  musculoskeletal≠B-OSE_Labeled_AE   chest≠I-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  myalgia≠B-OSE_Labeled_AE ,  pain≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   extremity≠I-OSE_Labeled_AE  
 *    Nervous≠B-NonOSE_AE   system≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  hypoesthesia≠B-OSE_Labeled_AE ,  intracranial≠B-OSE_Labeled_AE   hemorrhage≠I-OSE_Labeled_AE ,  paresthesia≠B-OSE_Labeled_AE ,  peripheral≠B-OSE_Labeled_AE   motor≠I-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE ,  peripheral≠B-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE ,  peripheral≠B-OSE_Labeled_AE   sensory≠I-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE  
 *    Psychiatric≠B-NonOSE_AE   disorders≠I-NonOSE_AE   :  anxiety≠B-OSE_Labeled_AE  
 *    Renal≠B-NonOSE_AE   and≠I-NonOSE_AE   urinary≠I-NonOSE_AE   disorders≠I-NonOSE_AE :    acute≠B-OSE_Labeled_AE   renal≠I-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  renal≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  renal≠B-OSE_Labeled_AE   impairment≠I-OSE_Labeled_AE  
 *    Respiratory≠B-NonOSE_AE  ,≠I-NonOSE_AE   thoracic≠I-NonOSE_AE   and≠I-NonOSE_AE   mediastinal≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  dysphonia≠B-OSE_Labeled_AE ,  epistaxis≠B-OSE_Labeled_AE ,  oropharyngeal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   edema≠I-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   hemorrhage≠I-OSE_Labeled_AE  
 *    Skin≠B-NonOSE_AE   and≠I-NonOSE_AE   subcutaneous≠I-NonOSE_AE   tissue≠I-NonOSE_AE   disorders≠I-NonOSE_AE :  erythema≠B-OSE_Labeled_AE ,  hyperhidrosis≠B-OSE_Labeled_AE ,  pruritus≠B-OSE_Labeled_AE ,  rash≠B-OSE_Labeled_AE  
 *    Vascular≠B-NonOSE_AE   disorders≠I-NonOSE_AE :  embolic≠B-OSE_Labeled_AE  and thrombotic  events≠I-OSE_Labeled_AE ,  venous≠I-OSE_Labeled_AE  (including  deep≠B-OSE_Labeled_AE   vein≠I-OSE_Labeled_AE   thrombosis≠I-OSE_Labeled_AE  and  pulmonary≠B-OSE_Labeled_AE   embolism≠I-OSE_Labeled_AE ),  hemorrhage≠B-OSE_Labeled_AE ,  hypotension≠B-OSE_Labeled_AE  
    Grade 3 and higher adverse reactions occurring at an incidence of > 1% include  febrile≠B-OSE_Labeled_AE   neutropenia≠I-OSE_Labeled_AE ,  cardiac≠B-OSE_Labeled_AE   arrest≠I-OSE_Labeled_AE ,  cardiac≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE   congestive≠I-OSE_Labeled_AE ,  pain≠B-OSE_Labeled_AE ,  sepsis≠B-OSE_Labeled_AE ,  urinary≠B-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE ,  hyperglycemia≠B-OSE_Labeled_AE ,  hyperkalemia≠B-OSE_Labeled_AE ,  hyperuricemia≠B-OSE_Labeled_AE ,  hypoalbuminemia≠B-OSE_Labeled_AE ,  hypocalcemia≠B-OSE_Labeled_AE ,  hyponatremia≠B-OSE_Labeled_AE ,  hypophosphatemia≠B-OSE_Labeled_AE ,  renal≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  renal≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE   acute≠I-OSE_Labeled_AE ,  renal≠B-OSE_Labeled_AE   impairment≠I-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   edema≠I-OSE_Labeled_AE , and  hypotension≠B-OSE_Labeled_AE .
 

   Laboratory Abnormalities  

 Table 13 describes Grade 3-4 laboratory abnormalities reported at a rate of > 10% for patients who received Kyprolis monotherapy.

 Table 13: Grade 3-4 Laboratory Abnormalities (> 10%) with Kyprolis Monotherapy 
    Laboratory≠B-NonOSE_AE   Abnormality≠I-NonOSE_AE       Kyprolis    20/56 mg/m      2      (N = 24)      Kyprolis    20/27 mg/m      2      (N = 598)     
  Decreased≠B-OSE_Labeled_AE   lymphocytes≠I-OSE_Labeled_AE   15 (63)          151 (25)          
  Decreased≠B-OSE_Labeled_AE   platelets≠I-OSE_Labeled_AE   11 (46)          184 (31)          
  Decreased≠B-OSE_Labeled_AE   hemoglobin≠I-OSE_Labeled_AE   7 (29)           132 (22)          
  Decreased≠B-OSE_Labeled_AE   total≠I-OSE_Labeled_AE   white≠I-OSE_Labeled_AE   blood≠I-OSE_Labeled_AE   cell≠I-OSE_Labeled_AE   count≠I-OSE_Labeled_AE   3 (13)           71 (12)           
  Decreased≠B-OSE_Labeled_AE   sodium≠I-OSE_Labeled_AE   2 (8)            69 (12)           
  Decreased≠B-OSE_Labeled_AE   absolute≠I-OSE_Labeled_AE   neutrophil≠I-OSE_Labeled_AE   count≠I-OSE_Labeled_AE   2 (8)            67 (11)           
           6.2       Postmarketing Experience
   The following additional adverse reactions were reported in the postmarketing experience with Kyprolis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:  hemolytic≠B-OSE_Labeled_AE   uremic≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE   (≠I-OSE_Labeled_AE  HUS≠I-OSE_Labeled_AE ),  gastrointestinal≠B-OSE_Labeled_AE   perforation≠I-OSE_Labeled_AE ,  pericarditis≠B-OSE_Labeled_AE .

